Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma

R. Schumacher-Kuckelkorn, A. Atra, ML. Belli, G. den Engelsman, P. Fréneaux, A. Gauthier, A. Heijlaerts-Klever, F. Scuderi, L. Senent Peris, S. Tewari, O. Zapletal, A. Ernst, F. Berthold

. 2021 ; 68 (3) : e28819. [pub] 20201127

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026037

BACKGROUND: The quantitative assessment of neuroblastoma cell content in bone marrow aspirates for response evaluation has been introduced recently. Data on the concordance of interobserver reports are lacking so far. METHODS: Investigators of seven European countries representing national reference or large oncological centers convened in 2016. They agreed to quantitatively assess routine bone marrow smears of the participating institutions and to discuss the discrepant results in joint meetings. RESULTS: From 2017 through 2019, three cytology rounds with 24, 28, and 28 bone marrow samples were run evaluating the representativity of the smears (yes/[restricted]/no) and the presence of tumor cells (yes/no and %). The comparison of the reports using κ (Fleiss) and α (Krippendorff) statistics demonstrated no robust reliabilities. The agreement on the representativity was moderate to poor, on the presence of tumor cells moderate to good, and on the percentage of tumor cells slight to moderate. Though the value of cytology is unquestioned to detect even tiny metastatic cells in bone marrow, the investigators unanimously agreed that a reliable quantification of the tumor cell content in bone marrow smears is unrealistic. For the key issue of representativity, a new practical definition was developed. CONCLUSION: For any work with bone marrow aspirates, the representativity of the material is of paramount importance. A practical definition is proposed. A reliable quantitative cytological assessment of tumor cell content in bone marrow aspirates is not feasible in metastatic neuroblastoma. Therefore, its use as response criterion should be reconsidered.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026037
003      
CZ-PrNML
005      
20211026133245.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.28819 $2 doi
035    __
$a (PubMed)33245195
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Schumacher-Kuckelkorn, Roswitha $u Department of Pediatric Oncology and Hematology, National Neuroblastoma Reference Cytology Lab, University of Cologne, Cologne, Germany
245    14
$a The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma / $c R. Schumacher-Kuckelkorn, A. Atra, ML. Belli, G. den Engelsman, P. Fréneaux, A. Gauthier, A. Heijlaerts-Klever, F. Scuderi, L. Senent Peris, S. Tewari, O. Zapletal, A. Ernst, F. Berthold
520    9_
$a BACKGROUND: The quantitative assessment of neuroblastoma cell content in bone marrow aspirates for response evaluation has been introduced recently. Data on the concordance of interobserver reports are lacking so far. METHODS: Investigators of seven European countries representing national reference or large oncological centers convened in 2016. They agreed to quantitatively assess routine bone marrow smears of the participating institutions and to discuss the discrepant results in joint meetings. RESULTS: From 2017 through 2019, three cytology rounds with 24, 28, and 28 bone marrow samples were run evaluating the representativity of the smears (yes/[restricted]/no) and the presence of tumor cells (yes/no and %). The comparison of the reports using κ (Fleiss) and α (Krippendorff) statistics demonstrated no robust reliabilities. The agreement on the representativity was moderate to poor, on the presence of tumor cells moderate to good, and on the percentage of tumor cells slight to moderate. Though the value of cytology is unquestioned to detect even tiny metastatic cells in bone marrow, the investigators unanimously agreed that a reliable quantification of the tumor cell content in bone marrow smears is unrealistic. For the key issue of representativity, a new practical definition was developed. CONCLUSION: For any work with bone marrow aspirates, the representativity of the material is of paramount importance. A practical definition is proposed. A reliable quantitative cytological assessment of tumor cell content in bone marrow aspirates is not feasible in metastatic neuroblastoma. Therefore, its use as response criterion should be reconsidered.
650    _2
$a vyšetřování kostní dřeně $x metody $7 D001856
650    _2
$a nádory kostní dřeně $x sekundární $7 D019046
650    _2
$a cytodiagnostika $x metody $7 D003581
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a neuroblastom $x patologie $7 D009447
650    _2
$a prognóza $7 D011379
650    _2
$a reprodukovatelnost výsledků $7 D015203
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Atra, Ayad $u Department of Paediatric Oncology/Haematology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
700    1_
$a Belli, Maria Luisa $u Department of Haematology and Oncology, Cytomorphology Laboratory, IRCCS, G. Gaslini Institute, Genoa, Italy
700    1_
$a den Engelsman, Gerda $u Diagnostisch Laboratorium, Prinses Maxima Centrum, Utrecht, The Netherlands
700    1_
$a Fréneaux, Paul $u Service de Pathologie, Pôle de médicine diagnosique et théranostic, Institut Curie, Paris, France
700    1_
$a Gauthier, Arnaud $u Service de Pathologie, Pôle de médicine diagnosique et théranostic, Institut Curie, Paris, France
700    1_
$a Heijlaerts-Klever, Anja $u Diagnostisch Laboratorium, Prinses Maxima Centrum, Utrecht, The Netherlands
700    1_
$a Scuderi, Francesca $u Department of Haematology and Oncology, Cytomorphology Laboratory, IRCCS, G. Gaslini Institute, Genoa, Italy
700    1_
$a Senent Peris, Leonor $u Department of Hematology, Cytomorphology Laboratory, Diagnosis Unit, La Fe University and Polytechnic Hospital, Valencia, Spain $u La Fe Health Research Institute, Hematology Research Group, Valencia, Spain $u Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Tewari, Sanjay $u Department of Paediatric Oncology/Haematology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
700    1_
$a Zapletal, Ondrej $u Department of Paediatric Haematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Ernst, Angela $u Faculty of Medicine and University Hospital Cologne, Institute of Medical Statistics and Computational Biology (IMSB), University of Cologne, Cologne, Germany
700    1_
$a Berthold, Frank $u Department of Pediatric Oncology and Hematology, National Neuroblastoma Reference Cytology Lab, University of Cologne, Cologne, Germany
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 68, č. 3 (2021), s. e28819
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33245195 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133251 $b ABA008
999    __
$a ok $b bmc $g 1714911 $s 1146544
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 68 $c 3 $d e28819 $e 20201127 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Logged in users only

Archiving options